Anti-53BP1 antibody

• IP

Supplier Data

Immunoprecipitation - Anti-53BP1 antibody (AB36823)

53BP1 was immunoprecipitated from 1 mg HEK293T whole cell lysate with ab36823 at 6 μg per reaction. Western blot was performed on the immunoprecipitate using ab243868 at a 1/1000 dilution.

Lane 1 : ab36823 IP in HEK293T whole cell lysate.

Lane 2 : Contol IgG in HEK293T whole cell lysate.

Detection : Chemiluminescence.

Exposure time : 10 seconds.

All lanes:

Immunoprecipitation - Anti-53BP1 antibody (ab36823)

Predicted band size: 214 kDa

false

• IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-53BP1 antibody (AB36823)

Immunohistochemical analysis of formalin-fixed, paraffin-embedded human prostate cancer tissue, labeling CTCF with ab36823 at a 1/5000 dilution. Detection : DAB.

• IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-53BP1 antibody (AB36823)

Immunohistochemical analysis of formalin-fixed, paraffin-embedded mouse renal cancer tissue, labeling CTCF with ab36823 at a 1/1000 dilution. Detection : DAB.

• WB

Supplier Data

Western blot - Anti-53BP1 antibody (AB36823)

Detection : Chemiluminescence.

All lanes:

Western blot - Anti-53BP1 antibody (ab36823) at 0.04 µg/mL

Lane 1:

HeLa cell nuclear extract at 50 µg

Lane 2:

HeLa cell nuclear extract at 5 µg

Lane 3:

TCMK1 mouse cell nuclear extract at 15 µg

Predicted band size: 214 kDa

false

Exposure time: 30s

• WB

CiteAb

Western blot - Anti-53BP1 antibody (AB36823)

53BP1 western blot using anti-53BP1 antibody ab36823. Publication image and figure legend from Onyango, D. O., Lee, G., et al., 2017, Oncotarget, PubMed 29212152.

ab36823 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab36823 please see the product overview.

Effects of PRPF8 and PlaB on BRCA1 levels and SSA in 53BP1-deficient cellsA. PlaB treatment causes a marked reduction in both BRCA1 protein and RNA. Cells were transfected with siRNA and cultured 3 days, and PlaB and DRB treatments were for 16 hr, prior to protein or RNA extraction, which were probed for BRCA1 and Actin by immunoblot and qRT-PCR, respectively. B. Loss of 53BP1 partially suppresses the SSA defect caused by PRPF8 depletion, but not PlaB treatment. Using Cas9, a derivative of the SA-GFP cell line with loss of 53BP1 (53BP1KO line) was generated, and reporter assays were performed as in Figure 1B and 1D. Shown are GFP+ frequencies normalized to parallel siCTRL or siCTRL/DMSO treated wells. Also shown is immunoblot confirmation of depletion of BRCA1 and PRPF8 by the respective siRNAs, and loss of 53BP1 in the 53BP1KO line. siPRPF8-2 graph, *p < 0.0001, parental line N = 15, 53BP1KON = 12. siPRPF8-4 graph *P = 0.001, N = 6. PlaB graph, parental line N = 12, 53BP1KON = 9.

false